Please assess the completion status of the following clinical trial:

Trial Title: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject/parent (or authorized designee) has provided written informed consent for the study.~* Subject is ≥15 and ≤45 years of age at the time of enrollment.~* Diagnosis of autistic disorder (AD) as confirmed by the gold standard clinical interview using Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria and administration of the Autism Diagnostic Observation Schedule-2.~* Subject, if female and of childbearing potential, is not lactating or pregnant.~* Subject, if female, is either not of childbearing potential or is practicing an acceptable effective method of birth control.~* Subject is willing to comply with all study requirements (including the requirements for stool sampling and biobanking) and to return to the study facility for the follow-up evaluations, as required.~Exclusion Criteria:~* Subject has known allergy or significant adverse reaction to L reuteri, Sephadex®, maltose, or related compounds.~* Subject has previously had GI surgery, intestinal obstruction, Clostridium difficile infection or diverticulitis.~* Subject has travelled outside of the USA in the 30 days prior to screening.~* Subject has had a diarrheal illness in 30 days prior to screening.~* Subject currently has a fever or active/uncontrolled gastrointestinal (GI) symptoms (e.g., nausea, vomiting, diarrhea, constipation, abdominal distention, abdominal pain/cramps, flatulence) or has had these within 14 days prior to screening. If the GI symptoms are stable, in the opinion of the investigator, the subject can be enrolled.~* Subject has any immunological/autoimmune disorder including, but not limited to, systemic lupus erythematosis, rheumatoid arthritis, Sjögren's syndrome, inflammatory bowel disease, or immunoglobulin-deficiency disorder, that would increase the risk to the subject or interfere with the evaluation of SB-121.~* Subject has a documented history of human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C~* Subject has implanted prosthetic devices including prosthetic heart valves.~* Subject has taken, or is taking, any of the following prohibited medications:~  1. A proton pump inhibitor within 2 weeks prior to screening~ 2. Use of supplemental probiotics within 2 weeks prior to screening except for yogurt~ 3. Current use of immunosuppressive medications, including corticosteroids~ 4. Treatment with monoclonal antibodies within 4 weeks prior to screening~ 5. Systemic antibiotics within 2 weeks prior to screening~* Subject has diabetes mellitus or is prediabetic.~* Subject has received any IP (or investigational device) within 30 days prior to screening.~* Subject has any of the following laboratory test results at Screening:~  1. An absolute neutrophil count of \<1.5 × 10\^9/L~ 2. alanine aminotransferase or aspartate aminotransferase \>1.5 × upper limit normal (ULN), total bilirubin \>1.5 × ULN (subjects with known Gilbert's Syndrome can be included)~ 3. serum creatinine \>1.5 × ULN~ 4. any other abnormal laboratory test that is clinically significant in the judgment of the investigator.~* Subject has an unstable medical condition or is otherwise considered unreliable or incapable, in the opinion of the investigator, of complying with the requirements of the protocol.~* Subject tests positive for drugs of abuse in a urine drug screen at screening.~* Subject has a history of alcohol abuse.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- SB-121 (Type: EXPERIMENTAL): One dose of SB-121 daily for 28 days according to the treatment group to which they are allocated.~Administration: Oral
- Placebo (Type: PLACEBO_COMPARATOR): One dose of placebo daily for 28 days according to the treatment group to which they are allocated.~Administration: Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete